Research programme: hypoxia inducible factor-proline dioxygenase inhibitors - Akebia Therapeutics

Drug Profile

Research programme: hypoxia inducible factor-proline dioxygenase inhibitors - Akebia Therapeutics

Alternative Names: AKB 6899

Latest Information Update: 07 Jan 2016

Price : $50

At a glance

  • Originator Akebia Therapeutics
  • Class Small molecules
  • Mechanism of Action Hypoxia-inducible factor-proline dioxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer; Eye disorders; Inflammatory bowel diseases

Most Recent Events

  • 04 Jan 2016 Preclinical data released by Akebia Therapeutics
  • 15 Apr 2015 Akebia Therapeutics plans a phase I trial for Cancer in USA
  • 01 Mar 2015 AKB 6899 is covered by patent protection in USA, Europe, Japan, China, South Korea, Brazil, Mexico, Israel, Russia and India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top